OC
TPST icon

Oppenheimer & Co’s Tempest Therapeutics TPST Stock Holding History

Oppenheimer & Co’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12
Closed -$26K – 1350
2018
Q3 		$26K Hold
12
– – ﹤0.01% 1337
2018
Q2 		$33K Sell
12
-1
-8% -$2.63K ﹤0.01% 1313
2018
Q1 		$31K Sell
13
-1
-7% -$3K ﹤0.01% 1317
2017
Q4 		$56K Sell
14
-4
-22% -$16.8K ﹤0.01% 1289
2017
Q3 		$72K Buy
18
+4
+29% +$17.1K ﹤0.01% 1260
2017
Q2 		$67K Buy
14
+2
+17% +$8.46K ﹤0.01% 1270
2017
Q1 		$66K Sell
12
-3
-20% -$14K ﹤0.01% 1257
2016
Q4 		$66K Sell
15
-4
-21% -$49.8K ﹤0.01% 1243
2016
Q3 		$393K Buy
19
+1
+6% +$18.1K 0.01% 896
2016
Q2 		$271K Hold
18
– – 0.01% 1007
2016
Q1 		$489K Sell
18
-1
-5% -$21.1K 0.01% 764
2015
Q4 		$545K Buy
19
+3
+19% +$98.9K 0.02% 737
2015
Q3 		$391K Buy
16
+12
+300% +$808K 0.01% 899
2015
Q2 		$344K Buy
+4
New +$366K 0.01% 1045

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $871M AUM 27.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Oppenheimer & Co's TPST Position: Q4 2018 in Review

Oppenheimer & Co sold out of Tempest Therapeutics (TPST) in Q4 2018, closing a stake of 12 shares — an estimated $26K sold.

Oppenheimer & Co first reported a position in TPST in Q2 2015 and held it in 14 quarters. The position peaked at $545K in Q4 2015. 30 funds tracked by Wall St. Rank hold TPST as of Q4 2018.

  • Oppenheimer & Co reported no remaining Tempest Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Oppenheimer & Co sold 12 Tempest Therapeutics shares in Q4 2018, an estimated $26K.
  • Oppenheimer & Co first reported a position in Tempest Therapeutics in Q2 2015 and held it in 14 quarters.
  • Oppenheimer & Co's Tempest Therapeutics position peaked at $545K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2018.

Based on Oppenheimer & Co's 13F filing for Q4 2018, filed 29 Jan 2019.